Previous NICE guidance (TA196) recommended against the use of imatinib for the adjuvant treatment of gastrointestinal stromal tumours after surgery. It is however listed in version 2.1 of the National Cancer Drugs Fund list for this indication, provided that certain criteria are met (completely resected tumour; high risk of relapse). The costing statement for this guidance estimates that 170 new people per year in England will be eligible for treatment with imatinib. The cumulative cost impact is £2.8 million in year 1, £4.3 million in year 2 and £5.1 million from year 3 onwards.